2015
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).
Petrylak D, Powles T, Bellmunt J, Braiteh F, Loriot Y, Cruz Zambrano C, Burris H, Kim J, Teng S, Bruey J, Hegde P, Abidoye O, Vogelzang N. A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). Journal Of Clinical Oncology 2015, 33: 4501-4501. DOI: 10.1200/jco.2015.33.15_suppl.4501.Peer-Reviewed Original Research
2014
Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer
Xiao Y, Rabe C, Kowanetz M, Powles T, Vogelzang N, Petrylak D, Loriot Y, Denker M, Nakamura R, Wu Q, Sumiyoshi T, Boyd Z, Teng S, Shen X, Fine G, Chen D, Hegde P. Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer. Journal For ImmunoTherapy Of Cancer 2014, 2: p131. PMCID: PMC4288443, DOI: 10.1186/2051-1426-2-s3-p131.Peer-Reviewed Original ResearchInhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
Powles T, Vogelzang N, Fine G, Eder J, Braiteh F, Loriot Y, Cruz Zambrano C, Bellmunt J, Burris H, Teng S, Shen X, Koeppen H, Hegde P, Chen D, Petrylak D. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). Journal Of Clinical Oncology 2014, 32: 5011-5011. DOI: 10.1200/jco.2014.32.15_suppl.5011.Peer-Reviewed Original Research